Ventyx Biosciences, Sanofi
Ventyx gets $27 million investment from Sanofi
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as it announced that French pharma major Sanofi (Euronext: SAN) has agreed to make a $27 million strategic investment in the company]. The closing of the transaction is expected to occur on September 23, 2024.
Ventyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical Trials
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target
Ventyx stock climbs 8% on $27M Sanofi investment
Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an as-converted price of $3.8243 per common share. Read more here.
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
“Sanofi is a global leader in immunological and inflammatory ... Data from both trials are expected in 2025. About Ventyx Biosciences Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients ...
GlobalData on MSN15h
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...
FierceBiotech21h
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
bovnews30m
Why Ventyx Biosciences Inc (VTYX) Stock is Currently 10.13% Above from Its 20-Day SMA?
Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.46 which represents a slight increase of $0.16 or 6.96% from the prior close of $2.3. The stock opened at $2.66 and ...
ENDPOINTS NEWS22h
Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
Sanofi: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...
Yahoo Finance22h
ATLANTIC SAPPHIRE TR (ASAT.OL)
It's another big week on Wall Street. The major indexes (^DJI,^GSPC, ^IXIC) are set to open higher, looking to build on last week's big gains. A number of Federal Reserve officials will speak about ...